Li Kang Biomedical Co., Ltd.

Total Valuation

Li Kang Biomedical Co., Ltd. carries a market capitalization of 1.15B, placing it among publicly traded companies globally. Its enterprise value stands at 1.21B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Li Kang Biomedical Co., Ltd. currently has 31.81M shares outstanding.

Valuation Ratios

Li Kang Biomedical Co., Ltd. trades at a trailing price-to-earnings ratio of 14.90. The price-to-sales ratio is 2.12, and the price-to-book ratio stands at 2.14.

Enterprise Valuation

On an enterprise value basis, Li Kang Biomedical Co., Ltd. trades at an EV/EBITDA multiple of 12.28 and an EV/FCF ratio of 2.86. The EV/Sales ratio of 2.05 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 12.28 provides insight into valuation relative to core operating earnings.

Financial Position

Li Kang Biomedical Co., Ltd. maintains a current ratio of 1.50, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.03, indicating elevated leverage, while an interest coverage ratio of 264.20 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Li Kang Biomedical Co., Ltd. posts a return on equity of 14.51 and a return on invested capital of 7.92.

Taxes

Over the trailing twelve months, Li Kang Biomedical Co., Ltd. has paid 20.23M in income taxes, reflecting an effective tax rate of 19.44.

Stock Price Statistics

Li Kang Biomedical Co., Ltd.'s stock has declined approximately -13.14837% over the past 52 weeks. The 50-day moving average sits at 37.49, while the 200-day moving average is 38.54.

Income Statement

Over the trailing twelve months, Li Kang Biomedical Co., Ltd. generated 589.21M in revenue and converted that into 83.82M in net income, yielding earnings per share of 2.63. EBITDA reached 98.28M, while operating income came in at 98.28M.

Balance Sheet

Li Kang Biomedical Co., Ltd. holds 190.22M in cash and equivalents against 148.39M in total debt, resulting in a net debt position of 49.44M. Total book value stands at 583.36M, with working capital of 84.59M providing operational flexibility.

Cash Flow

Li Kang Biomedical Co., Ltd. produced 92.15M in operating cash flow over the past twelve months. After subtracting -329.54M in capital expenditures, free cash flow totaled -237.40M - equivalent to -7.46 per share.

Margins

Li Kang Biomedical Co., Ltd. operates with a gross margin of 67.59, reflecting its pricing power and cost economics. The operating margin of 16.68 and net profit margin of 14.23 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Li Kang Biomedical Co., Ltd.'s most recent stock split took place on December 27, 2023 with a 500:517 split ratio.

Scores

Li Kang Biomedical Co., Ltd. posts an Altman Z-Score of 4.65, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.